Zoetis (ZTS) Competitors

Horizon Therapeutics Public (NASDAQ:HZNP) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.

Does the media favor HZNP or ZTS?

In the previous week, Horizon Therapeutics Public had 8 more articles in the media than Zoetis. MarketBeat recorded 10 mentions for Horizon Therapeutics Public and 2 mentions for Zoetis. Zoetis' average media sentiment score of 0.81 beat Horizon Therapeutics Public's score of 0.47 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Horizon Therapeutics Public	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, HZNP or ZTS?

Zoetis has higher revenue and earnings than Horizon Therapeutics Public. Zoetis is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Therapeutics Public	$3.58 billion	6.36	$521.48 million	$1.59	62.53
Zoetis	$8.08 billion	9.40	$2.11 billion	$4.43	37.09

Do analysts recommend HZNP or ZTS?

Horizon Therapeutics Public currently has a consensus price target of $111.42, indicating a potential upside of 12.07%. Zoetis has a consensus price target of $221.14, indicating a potential upside of 34.61%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Horizon Therapeutics Public.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Therapeutics Public	0 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.27
Zoetis	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is HZNP or ZTS more profitable?

Zoetis has a net margin of 25.59% compared to Horizon Therapeutics Public's net margin of 10.40%. Zoetis' return on equity of 50.26% beat Horizon Therapeutics Public's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Therapeutics Public	10.40%	20.31%	11.37%
Zoetis	25.59%	50.26%	16.24%

Do insiders & institutionals believe in HZNP or ZTS?

91.0% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 90.2% of Zoetis shares are owned by institutional investors. 2.5% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 0.1% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk and volatility, HZNP or ZTS?

Horizon Therapeutics Public has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Does the MarketBeat Community prefer HZNP or ZTS?

Horizon Therapeutics Public received 26 more outperform votes than Zoetis when rated by MarketBeat users. Likewise, 78.15% of users gave Horizon Therapeutics Public an outperform vote while only 77.57% of users gave Zoetis an outperform vote.

Company	Underperform	Outperform
Horizon Therapeutics Public	Outperform Votes 894 78.15%	Underperform Votes 250 21.85%
Zoetis	Outperform Votes 868 77.57%	Underperform Votes 251 22.43%

Summary

Zoetis beats Horizon Therapeutics Public on 11 of the 18 factors compared between the two stocks.